BioNTech SE ADR buy MoneyMoney
Start price
18.04.24
/
0%
€81.35
Target price
18.04.25
€100.00
Performance (%)
-3.69%
Price
21:43
€78.35
Summary
This prediction is currently active. With a performance of -3.69%, the BUY prediction for BioNTech SE ADR by MoneyMoney is down slightly. This prediction currently runs until 18.04.25. The prediction end date can be changed by MoneyMoney at any time. This prediction was marked as speculative and is excluded from MoneyMoney's performance statistics.Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
BioNTech SE ADR | 7.896% | 7.896% |
iShares Core DAX® | 1.665% | 1.692% |
iShares Nasdaq 100 | -0.475% | 1.483% |
iShares Nikkei 225® | 2.620% | 4.475% |
iShares S&P 500 | -0.091% | 1.099% |
According to MoneyMoney what are the pros and cons of BioNTech SE ADR for the foreseeable future?
Pros
EBIT growth > 30% per year expected
Higher EBIT margin than peer group
Fair valuation
Differentiated customer and product portfolio
Valuable balance sheet
High Investments for future growth
Future proof or reliable business model
Capable Management
Innovative
Growths faster than the competition
Stable Large shareholder and/or long term investor
Revenue growth > 30% per year expected
Well known brand
Top 10 in its market
Could be worthwhile Investment >10% per year
Good culture
Strong uniques
positive Cash Flow expected
Sustainability is important
Good rating
Cons
Higher risks for its business
Significant cyclical dependencies
Low dividend yield expected
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
Comments by MoneyMoney for this prediction
In the thread Biontech SE diskutieren
Buy mit Kursziel 100,0
Stopped prediction by MoneyMoney for BioNTech SE ADR
BioNTech SE ADR
Start price
Target price
Perf. (%)
€160.55
11.12.22
11.12.22
€120.00
11.12.23
11.12.23
-42.05%
12.12.23
12.12.23
EBIT growth > 30% per year expected
Higher EBIT margin than peer group
Fair valuation
Higher risks for its business
BioNTech SE ADR
Start price
Target price
Perf. (%)
€210.00
14.11.21
14.11.21
€185.00
14.11.22
14.11.22
-25.98%
15.11.22
15.11.22
EBIT growth > 30% per year expected
Higher EBIT margin than peer group
Fair valuation
Higher risks for its business
BioNTech SE ADR
Start price
Target price
Perf. (%)
€67.74
13.07.20
13.07.20
€250.00
04.11.21
04.11.21
254.74%
05.11.21
05.11.21
EBIT growth > 30% per year expected
Higher EBIT margin than peer group
Fair valuation
Higher risks for its business